On 27 March, researchers from the Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) project published an article entitled “Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies” in the journal EJNMMI Research. The purpose of the study was to define optimal dual-time-window acquisition protocols for [18F]florbetaben and [18F]flutemetamol, both in terms of patient comfort and throughput, while maintaining high quantitative accuracy. These simulations were focused on early stages of the disease, given the potential value of amyloid imaging to guide interventions aimed at secondary prevention of Alzheimer’s disease dementia. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.